Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**ZymaDerm** is a branded homeopathic topical liquid developed and marketed by Naturopathix for the treatment of **molluscum contagiosum**. It is a **multi-ingredient combination product** containing homeopathic active ingredients including **argentum nitricum**, **echinacea angustifolia**, **fucus vesiculosus**, and **thuja occidentalis**, with additional non-homeopathic excipients such as tea tree oil, Backhousia citriodora oil, clove oil, selenium-rich canola oil, and fractionated coconut oil. It is applied directly to skin lesions twice daily and is marketed primarily for pediatric and adult patients with molluscum contagiosum. The product is positioned as a homeopathic medicine rather than an evidence-based targeted pharmaceutical, and a precise molecular mechanism of action for its clinical effect has not been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ZymaDerm.